10-K: Cryo-Cell International, Inc. Files 10-K Report, Details Financials and Strategic Initiatives

Cryo-Cell International, Inc. released its annual 10-K report, outlining its financial performance, strategic initiatives, and risk factors for the fiscal year ended November 30, 2023.

Summary

• Cryo-Cell International, Inc. reported a 3% increase in revenue, reaching $31.3 million for the fiscal year ended November 30, 2023.
• The company's processing and storage fees increased by 3.4%, totaling $30.8 million, driven by a 5% rise in recurring annual storage fees, despite an 8% decrease in new domestic cord blood specimens processed.
• Product revenue decreased to $66,456, while public cord blood banking revenue saw a slight increase to $481,148.
• Cost of sales decreased by 4% to $8.4 million, primarily due to a reduction in new domestic cord blood specimens processed.
• Selling, general, and administrative expenses rose by 10% to $17.1 million, while research and development expenses increased significantly to $1.2 million.
• The company recognized a $3.7 million impairment of public inventory and a $13.1 million impairment of Duke assets.
• Interest expense decreased to $1.2 million, and the company recorded a gain on an interest rate swap of $122,113.
• The company reported a net loss of $9.5 million, compared to a net income of $2.8 million in the previous year.
• The company's cash and cash equivalents decreased to $406,067 from $1.7 million in the previous year.
• The company anticipates capital expenditures of approximately $5 million over the next 12 months for property build out, equipment purchases, obligations under the Patent and Technology License Agreement with Duke University and software enhancements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth but significant losses and impairments. The company faces challenges in achieving profitability and realizing the full value of its assets. The future outlook is uncertain, with reliance on clinical trials and new business ventures.

Positives

• The company experienced a 5% increase in recurring annual storage fee revenue.
• Public cord blood banking revenue saw a slight increase.
• The company has a revolving line of credit available for future funding.
• The company is expanding its cryopreservation and cold storage business with a new facility in North Carolina.

Negatives

• The company experienced an 8% decrease in the number of new domestic cord blood specimens processed.
• Product revenue decreased to $66,456.
• The company recognized a $3.7 million impairment of public inventory.
• The company recognized a $13.1 million impairment of Duke assets.
• The company reported a net loss of $9.5 million for the fiscal year.
• Cash and cash equivalents decreased to $406,067.

Risks

• The company operates in a rapidly changing environment with risks including technological changes, competition, and regulatory hurdles.
• The company may need to raise additional capital to fund operations, clinical trials, and facility expansions.
• The company's success depends on the continued market acceptance of stem cell preservation.
• The company faces competition from other stem cell preservation businesses and providers of stem storage services.
• The company's operations are vulnerable to damage or interruption from various events, including equipment failure and natural disasters.
• The company is subject to substantial government regulation, including FDA inspections.
• The company's international operations are subject to risks, including intellectual property protection and compliance with foreign laws.
• The company's information systems are critical to its business and are vulnerable to security breaches.
• The company may be subject to third-party claims alleging infringement of their patents and proprietary rights.
• The company may be subject to securities class action litigation.

Future Outlook

The company anticipates using a substantial amount of cash to fund clinical trials related to the Duke Agreement and to develop its biopharmaceutical manufacturing capabilities. The company projects to open the Cryo-Cell Institute for Cellular Therapies and begin infusing patients during fiscal 2024.

Management Comments

• The company intends to transfer the assets related to the Patent and Technology License Agreement with Duke University and certain other assets into a newly formed, wholly-owned subsidiary to provide more financial flexibility to fund future projects.
• The company also intends to explore spinning off this subsidiary to the Companys shareholders.

Industry Context

The stem cell preservation market is becoming increasingly competitive, with approximately 25 other national private cord blood banks. The company believes it is well-positioned to compete due to its longevity, experience, value-based pricing, and state-of-the-art facilities.

Comparison to Industry Standards

• The document does not provide specific financial benchmarks for the cord blood banking industry, making direct comparisons challenging.
• However, the company highlights its AABB and FACT accreditations, suggesting a commitment to quality standards.
• The company's focus on expanding into biopharmaceutical manufacturing and operating clinics is a strategic move that differentiates it from some competitors.
• The company's collaboration with Duke University and its focus on clinical trials for new indications are also unique aspects of its business model.
• The company's financial results, particularly the net loss and impairment charges, indicate challenges in achieving profitability and realizing the full value of its assets.

Legal Proceedings

• The company is involved in a lawsuit, Lindsey Lehr v. Cryo-Cell International, Inc., which has been moved to arbitration.
• The company believes the plaintiffs claims are unlikely to prevail and intends to contest the action vigorously.

Related Party Transactions

• David Portnoy, the Companys Chairman and Co-Chief Executive officer, is the brother of the Companys Co-Chief Executive Officer Mark Portnoy.
• The Companys Audit Committee Chairman, Harold Berger, provides accounting services to the Companys Co-Chief Executive Officer Mark Portnoy and to PartnerCommunity, Inc.
• The Companys Chairman and Co-Chief Executive Officer, David Portnoy, serves as the Chairman of the Board of PartnerCommunity, Inc.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and impairment charges.
• Employees may be affected by potential changes in the company's structure and operations.
• Customers may be impacted by the company's expansion into new services and technologies.
• Suppliers may be affected by the company's changing needs and priorities.
• Creditors may be concerned about the company's financial performance and ability to repay debt.

Next Steps

• The company plans to open the Cryo-Cell Institute for Cellular Therapies and begin infusing patients during fiscal 2024.
• The company intends to fund additional clinical trials related to the Duke Agreement.
• The company plans to develop its biopharmaceutical manufacturing capabilities related to MSCs.
• The company intends to transfer the assets related to the Patent and Technology License Agreement with Duke University and certain other assets into a newly formed, wholly-owned subsidiary.
• The company also intends to explore spinning off this subsidiary to the Companys shareholders.

Key Dates

Keywords

cord blood, stem cells, cryopreservation, public banking, tissue storage, biopharmaceutical, clinical trials, Duke University, revenue, EBITDA, financial report, MSC, PrepaCyte CB